ARCT Stock Price | Arcturus Therapeutics Holdings Inc P/E, Revenue, EPS, & Forecasts

Arcturus Therapeutics Holdings Inc • ARCT

ARCT current price

$17.55-40.41%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-9.72%

-7.78%

-16.50%

-38.82%

-40.41%

MAX

-35.64%

About Arcturus Therapeutics Holdings Inc

Ticker

ARCT

Trading on

NASDAQ

ISIN

US03969T1097

Industry

Biotechnology

Sector

Healthcare

CEO

Joseph E. Payne M.Sc.

Headquarters

10628 Science Center Drive, San Diego, CA, United States, 92121

Employees

180

Website

https://arcturusrx.com

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Metrics

BasicAdvanced

Market cap

$475M

P/E ratio

EPS

-$2.33

Dividend Yield

0.00%

Beta

2.64

Forward P/E ratio

2.48

EBIDTA

$-77M

Ex dividend date

Price & volume

Market cap

$475M

Average daily volume

0.5M

90-day return

-16.50%

30-day return

-7.78%

7-day return

-9.72%

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

2.48

PEG ratio

Trailing P/E

Price to sales

2.96

Price to book

1.86

Earnings

EPS

-$2.33

EPS estimate (current quarter)

-$1.22

EPS estimate (next quarter)

-$0.27

EBITDA

$-77M

Revenues (TTM)

$160M

Revenues per share (TTM)

$5.96

Technicals

Beta

2.64

52-week High

$45.00

52-week Low

$14.93

50-day moving average

$19.34

200-day moving average

$25.33

Short ratio

9.41

Short %

25.29%

Management effectiveness

ROE (TTM)

23.12%

ROA (TTM)

12.15%

Profit margin

39.05%

Gross profit margin

$62.9M

Operating margin

25.77%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

7.70%

Share stats

Outstanding Shares

27.1M

Float

24.8M

Insiders %

8.46%

Institutions %

90.21%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$79.47

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.32

-$0.99

67.68%

Q4 • 23Beat

-$1.00

-$1.19

15.97%

Q1 • 24Beat

-$0.64

-$1.60

60.00%

Q2 • 24Beat

-$0.26

-$1.22

78.69%

Q3 • 24Beat

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$46M

$-17.2M

37.45%

Q2 • 24

$38.8M

$-6.9M

17.78%

Q3 • 24

15.58%

59.90%

52.51%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$389M

$130M

33.46%

Q2 • 24

$371M

$109M

29.35%

Q3 • 24

4.62%

16.33%

12.28%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-29.8M

$-0.3M

$2.4M

$-30.2M

Q2 • 24

$-23.8M

$0.7M

$-23.5M

Q3 • 24

20.39%

70.70%

22.14%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Fear

+1.5

-0.38

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Arcturus Therapeutics Holdings Inc share?

Arcturus Therapeutics Holdings Inc shares are currently traded for $17.55 per share.

How many shares does Arcturus Therapeutics Holdings Inc have?

Arcturus Therapeutics Holdings Inc currently has 27.1M shares.

Does Arcturus Therapeutics Holdings Inc pay dividends?

No, Arcturus Therapeutics Holdings Inc doesn't pay dividends.

What is Arcturus Therapeutics Holdings Inc 52 week high?

Arcturus Therapeutics Holdings Inc 52 week high is $45.00.

What is Arcturus Therapeutics Holdings Inc 52 week low?

Arcturus Therapeutics Holdings Inc 52 week low is $14.93.

What is the 200-day moving average of Arcturus Therapeutics Holdings Inc?

Arcturus Therapeutics Holdings Inc 200-day moving average is $25.33.

Who is Arcturus Therapeutics Holdings Inc CEO?

The CEO of Arcturus Therapeutics Holdings Inc is Joseph E. Payne M.Sc..

How many employees Arcturus Therapeutics Holdings Inc has?

Arcturus Therapeutics Holdings Inc has 180 employees.

What is the market cap of Arcturus Therapeutics Holdings Inc?

The market cap of Arcturus Therapeutics Holdings Inc is $475M.

What is the P/E of Arcturus Therapeutics Holdings Inc?

The current P/E of Arcturus Therapeutics Holdings Inc is null.

What is the EPS of Arcturus Therapeutics Holdings Inc?

The EPS of Arcturus Therapeutics Holdings Inc is -$2.33.

What is the PEG Ratio of Arcturus Therapeutics Holdings Inc?

The PEG Ration of Arcturus Therapeutics Holdings Inc is null.

What do analysts say about Arcturus Therapeutics Holdings Inc?

According to the analysts Arcturus Therapeutics Holdings Inc is considered a buy.

Arcturus Therapeutics Holdings Inc news

thumbs_up_down

•Neutral

Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Piper Sandler 36th Annual Healthcare Conference (Fireside Chat) Tuesday, December 3, 2024 (4:30 p.m. ET) Citi's 2024 Global Healthcare Con.

Business Wire•26 Nov 2024, 21:01

thumbs_up_down

•Neutral

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at Jefferies London Healthcare Conference in London, on Wednesday, November 20, 2024, at 9:30 am GMT. A webcast and replay of the presentation will be available on the Investor Rela.

Business Wire•19 Nov 2024, 01:00

thumb_down_alt

•Negative

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2 proof-of-concept study, using LUNAR-OTC for treatment of patients with OTC Deficiency, expected 1st half of 2025.

Seeking Alpha•14 Nov 2024, 18:44